CD73/NT5E在胶质母细胞瘤中的研究进展

doi:10.3969/j.issn.1006-5725.2024.03.026

Abstract

Abstract:

Glioma is the most common primary central nervous system tumor， mainly derived from glial cells， with strong invasiveness， easy recurrence， and poor prognosis. Glioblastoma is a high-grade glioma with the highest degree of malignancy. The clinical treatment method is mainly surgical resection， supplemented by comprehensive treatment such as radiotherapy， chemotherapy， and electric field therapy， but the treatment effect is not satisfactory. In recent years， with the rapid development of the field of tumor immunotherapy， CD73 is a novel immune checkpoint related to adenosine metabolism， which can promote tumor progression by inhibiting anti?tumor immune responses and promoting angiogenesis. This article systematically reviews the mechanism of action of CD73 and discusses its biological role and application in glioma， aiming to provide potential treatment options for glioma patients.

Key words: Glioblastoma, CD73/NT5E, adenosine, immune checkpoint, immunotherapy

CLC Number:

R739.41

Jiang SHAO,Lin LI,Yansong GUO,Chengyuan SUN,Xichao WEN,Kebin ZHENG,Yanfang SHI. Research progress of CD73/NT5E in glioblastoma[J]. The Journal of Practical Medicine, 2024, 40(3): 428-431.

References 42

1	PARK J W. Metabolic Rewiring in Adult-Type Diffuse Gliomas［J］. Int J Mol Sci， 2023，24（8）： 7348. doi:10.3390/ijms24087348 doi: 10.3390/ijms24087348
2	曾昭穆，牛双，姬焱鑫，等. 长链非编码RNA多角度调控胶质瘤化疗耐药［J］. 实用医学杂志，2022，38（16）：1998-2001. doi:10.3969/j.issn.1006-5725.2022.16.003 doi: 10.3969/j.issn.1006-5725.2022.16.003
3	李琳，刘超，邵将，等. 肿瘤电场治疗在神经胶质瘤治疗中的研究进展［J］. 实用医学杂志， 2022，38（22）： 2763-2767. doi:10.3969/j.issn.1006-5725.2022.22.001 doi: 10.3969/j.issn.1006-5725.2022.22.001
4	VENKATESHAPPA C， NARAYANAN K， KOTHANDARAMAN P， et al. Novel， potent and orally bioavailable small molecule CD73 inhibitors for cancer immunotherapy［J］. Cancer Res， 2021，81（）： 1713. doi:10.1158/1538-7445.am2021-1713 doi: 10.1158/1538-7445.am2021-1713
5	KEPP O， BEZU L， YAMAZAKI T， et al. ATP and cancer immunosurveillance［J］. EMBO J， 2021，40（13）： e108130. doi:10.15252/embj.2021108130 doi: 10.15252/embj.2021108130
6	SUWARA J， RADZIKOWSKA-CIECIURA E， CHWOROS A， et al. The ATP-dependent Pathways and Human Diseases［J］. Curr Med Chem， 2023，30（11）： 1232-1255. doi:10.2174/0929867329666220322104552 doi: 10.2174/0929867329666220322104552
7	XIA C， YIN S， TO K， et al. CD39/CD73/A2AR pathway and cancer immunotherapy［J］. Mol Cancer， 2023，22（1）： 44. doi:10.1186/s12943-023-01733-x doi: 10.1186/s12943-023-01733-x
8	TAKAMATSU D， KIYOZAWA D， KOHASHI K， et al. Prognostic impact of CD73/adenosine 2A receptor （A2AR） in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features［J］. Pathol Res Pract， 2023，244： 154423. doi:10.1016/j.prp.2023.154423 doi: 10.1016/j.prp.2023.154423
9	DA M， CHEN L， ENK A， et al. The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells［J］. Front Immunol， 2022，13： 914799. doi:10.3389/fimmu.2022.914799 doi: 10.3389/fimmu.2022.914799
10	CHEN S， WAINWRIGHT D A， WU J D， et al. CD73： an emerging checkpoint for cancer immunotherapy［J］. Immunotherapy， 2019，11（11）： 983-997. doi:10.2217/imt-2018-0200 doi: 10.2217/imt-2018-0200
11	SUN B Y， YANG Z F， WANG Z T， et al. Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma［J］. World J Surg Oncol， 2023，21（1）： 90. doi:10.1186/s12957-023-02970-6 doi: 10.1186/s12957-023-02970-6
12	BENSUSSEN A， SANTANA M A， RODRÍGUEZ-JORGE O. Metabolic alterations impair differentiation and effector functions of CD8+ T cells［J］. Front Immunol， 2022，13： 945980. doi:10.3389/fimmu.2022.945980 doi: 10.3389/fimmu.2022.945980
13	BYSTROM J， TAHER T E， HENSON S M， et al. Metabolic requirements of Th17 cells and of B cells： Regulation and defects in health and in inflammatory diseases［J］. Front Immunol， 2022，13： 990794. doi:10.3389/fimmu.2022.990794 doi: 10.3389/fimmu.2022.990794
14	MAHESHWARI S， DWYER L J， SÎRBULESCU R F. Inflammation and immunomodulation in central nervous system injury - B cells as a novel therapeutic opportunity［J］. Neurobiol Dis， 2023，180： 106077. doi:10.1016/j.nbd.2023.106077 doi: 10.1016/j.nbd.2023.106077
15	JANSEN K， CEVHERTAS L， MA S， et al. Regulatory B cells， A to Z［J］. Allergy， 2021，76（9）： 2699-2715. doi:10.1111/all.14763 doi: 10.1111/all.14763
16	GAO Z， WANG L， SONG Z， et al. Intratumoral CD73： An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts［J］. Front Immunol， 2022，13： 954039. doi:10.3389/fimmu.2022.954039 doi: 10.3389/fimmu.2022.954039
17	BRAUNECK F， SEUBERT E， WELLBROCK J， et al. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML［J］. Int J Mol Sci， 2021，22（23）：12919. doi:10.3390/ijms222312919 doi: 10.3390/ijms222312919
18	SONIGO G， BOZONNAT A， DUMONT M， et al. Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome［J］. Blood， 2022，139（17）： 2712-2716. doi:10.1182/blood.2021014782 doi: 10.1182/blood.2021014782
19	KAMAI T， KIJIMA T， TSUZUKI T， et al. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival［J］. Cancer Immunol Immunother， 2021，70（7）： 2009-2021. doi:10.1007/s00262-020-02843-x doi: 10.1007/s00262-020-02843-x
20	SUN P， ZHENG X， LI X. The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment［J］. J Oncol， 2022，2022： 4330329. doi:10.1155/2022/4330329 doi: 10.1155/2022/4330329
21	EBERHARDT N， BERGERO G， MAZZOCCO M Y， et al. Purinergic modulation of the immune response to infections［J］. Purinergic Signal， 2022，18（1）： 93-113. doi:10.1007/s11302-021-09838-y doi: 10.1007/s11302-021-09838-y
22	ELSAGHIR A， EL-SABAA E， AHMED A K， et al. The Role of Cluster of Differentiation 39 （CD39） and Purinergic Signaling Pathway in Viral Infections［J］. Pathogens， 2023，12（2）：279. doi:10.3390/pathogens12020279 doi: 10.3390/pathogens12020279
23	CASEY M， SEGAWA K， LAW S C， et al. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma［J］. Leukemia， 2023，37（2）： 379-387. doi:10.1038/s41375-022-01794-9 doi: 10.1038/s41375-022-01794-9
24	IZAWA M， TANAKA N， MURAKAMI T， et al. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer［J］. Lab Invest， 2023，103（4）： 100040. doi:10.1016/j.labinv.2022.100040 doi: 10.1016/j.labinv.2022.100040
25	BAJRACHARYA B， SHRESTHA D， TALVANI A， et al. The Ecto-5'nucleotidase/CD73 Mediates Leishmania amazonensis Survival in Macrophages［J］. Biomed Res Int， 2022，2022： 9928362. doi:10.1155/2022/9928362 doi: 10.1155/2022/9928362
26	ANDERSEN J K， MILETIC H， HOSSAIN J A. Tumor-Associated Macrophages in Gliomas-Basic Insights and Treatment Opportunities［J］. Cancers （Basel）， 2022，14（5）：1319. doi:10.3390/cancers14051319 doi: 10.3390/cancers14051319
27	WEI Q， ZHANG L， ZHAO N， et al. Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy［J］. Front Immunol， 2022，13： 1012927. doi:10.3389/fimmu.2022.1012927 doi: 10.3389/fimmu.2022.1012927
28	NIE J， WANG D， LI M. The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer［J］. Clin Transl Oncol， 2023，25（10）： 2832-2840. doi:10.1007/s12094-023-03160-2 doi: 10.1007/s12094-023-03160-2
29	KOWASH R R， AKBAY E A. Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer［J］. Front Immunol， 2023，14： 1130358. doi:10.3389/fimmu.2023.1130358 doi: 10.3389/fimmu.2023.1130358
30	LI L， WANG L， LI J， et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer［J］. Cancer Res， 2018，78（7）： 1779-1791. doi:10.1158/0008-5472.can-17-2460 doi: 10.1158/0008-5472.can-17-2460
31	KIM H M， KANG M J， SONG S O. Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes： A Population-Based Study in Korea［J］. Endocrinol Metab （Seoul）， 2022，37（6）： 929-937. doi:10.3803/enm.2022.1613 doi: 10.3803/enm.2022.1613
32	WANG M， JIA J， CUI Y， et al. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion［J］. Cell Death Dis， 2021，12（11）： 1065. doi:10.1038/s41419-021-04359-3 doi: 10.1038/s41419-021-04359-3
33	AZAMBUJA J H， GELSLEICHTER N E， BECKENKAMP L R， et al. CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth［J］. Mol Neurobiol， 2019，56（5）： 3260-3279. doi:10.1007/s12035-018-1240-4 doi: 10.1007/s12035-018-1240-4
34	GELSLEICHTER N E， AZAMBUJA J H， RUBENICH D S， et al. CD73 in glioblastoma： Where are we now and what are the future directions？［J］. Immunol Lett， 2023，256-257： 20-27. doi:10.1016/j.imlet.2023.03.005 doi: 10.1016/j.imlet.2023.03.005
35	AZAMBUJA J H， SCHUH R S， MICHELS L R， et al. Blockade of CD73 delays glioblastoma growth by modulating the immune environment［J］. Cancer Immunol Immunother， 2020，69（9）： 1801-1812. doi:10.1007/s00262-020-02569-w doi: 10.1007/s00262-020-02569-w
36	TSIAMPALI J， NEUMANN S， GIESEN B， et al. Enzymatic activity of CD73 modulates invasion of gliomas via epithelial-mesenchymal transition-like reprogramming［J］. Pharmaceuticals （Basel）， 2020，13（11）： 378. doi:10.3390/ph13110378 doi: 10.3390/ph13110378
37	ZHANG S， LI B， TANG L， et al. Disruption of CD73-Derived and Equilibrative Nucleoside Transporter 1-Mediated Adenosine Signaling Exacerbates Oxygen-Induced Retinopathy［J］. Am J Pathol， 2022，192（11）： 1633-1646. doi:10.1016/j.ajpath.2022.07.014 doi: 10.1016/j.ajpath.2022.07.014
38	YAN A， JOACHIMS M L， THOMPSON L F， et al. CD73 promotes glioblastoma pathogenesis and enhances its chemoresistance via A2B adenosine receptor signaling［J］. J Neurosci， 2019，39（22）： 4387-4402. doi:10.1523/jneurosci.1118-18.2019 doi: 10.1523/jneurosci.1118-18.2019
39	GOSWAMI S， WALLE T， CORNISH A E， et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma［J］. Nat Med， 2020，26（1）： 39-46. doi:10.1038/s41591-019-0694-x doi: 10.1038/s41591-019-0694-x
40	AZAMBUJA J H， SCHUH R S， MICHELS L R， et al. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model［J］. Cancer Chemother Pharmacol， 2020，85（6）： 1177-1182. doi:10.1007/s00280-020-04077-1 doi: 10.1007/s00280-020-04077-1
41	SAHA D， MARTUZA R L， RABKIN S D. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade［J］. Cancer Cell， 2017，32（2）： 253-267. doi:10.1016/j.ccell.2017.07.006 doi: 10.1016/j.ccell.2017.07.006
42	LI L， TIAN Y. The role of metabolic reprogramming of tumor-associated macrophages in shaping the immunosuppressive tumor microenvironment［J］. Biomed Pharmacother， 2023，161： 114504. doi:10.1016/j.biopha.2023.114504 doi: 10.1016/j.biopha.2023.114504

[1]	Yuxuan DING,Lining GUO,Jiayi SHEN,Lijun. WANG. Safety and efficacy of radiotherapy and PD⁃1/PD⁃L1 inhibitor + TKI for MSS/pMMR colorectal cancer with liver metastases [J]. The Journal of Practical Medicine, 2024, 40(9): 1293-1297.
[2]	Xiaona MENG,Xu SUN,Huaimin LIU. Advances in the study of immune checkpoint inhibitors⁃related colitis [J]. The Journal of Practical Medicine, 2024, 40(9): 1314-1319.
[3]	Yuqiao ZHANG,Weijian MEI. Landmark Achievements in Treating Solid Tumors with Immune Checkpoint Inhibitors [J]. The Journal of Practical Medicine, 2024, 40(2): 272-277.
[4]	Zhaochen SUN,Junyan JIANG,Yitian. CHEN. Advancements in CAR⁃T cell research for the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(18): 2640-2646.
[5]	Shengfang YUAN,Bu WANG,Baoli XIANG,Jianqing ZHAO,Jingjing SHEN,Zhihua. ZHANG. Prediction of immune therapy efficacy and prognosis for advanced non-small cell lung cancer using peripheral blood circulation tumor DNA [J]. The Journal of Practical Medicine, 2024, 40(15): 2110-2115.
[6]	Ziqi DING,Qian. ZHANG. Research progress in T cell exhaustion and its relationship with respiratory diseases [J]. The Journal of Practical Medicine, 2024, 40(13): 1895-1900.
[7]	Liu LI,Qinghou ZHENG,Yu WANG,Le WANG,Qincong CHEN,Shuo WANG. Application value of adenosine injection in paclitaxel release coronary balloon catheter dilation [J]. The Journal of Practical Medicine, 2024, 40(12): 1712-1718.
[8]	Yawei ZHANG,Hongjin SHI,Shi FU,Jiansong WANG,Haifeng WANG. Research progress in biological role of TIGIT and its application in bladder cancer [J]. The Journal of Practical Medicine, 2024, 40(12): 1762-1766.
[9]	Huinan ZHOU,Kewei QIN,Lijun. ZHOU. Current research status and clinical application progress of the immune checkpoint LAG⁃3 and its targeting drugs [J]. The Journal of Practical Medicine, 2024, 40(11): 1607-1612.
[10]	Xizhi WEN,Xiaoshi. ZHANG. Immunotherapy based on neoantigen： A personalized treatment strategy for melanoma [J]. The Journal of Practical Medicine, 2024, 40(10): 1331-1337.
[11]	WU Kaiyi, LÜ Xuedong, HE Haiyan, CHEN Jinliang. . Progress in the application of cryoablation combined with immunotherapy in the treatment of NSCLC [J]. The Journal of Practical Medicine, 2023, 39(8): 1058-1062.
[12]	ZHANG Xijie, LI Xin, ZHOU Wence.. Research progress of combined immunotherapy for metastatic pancreas cancer [J]. The Journal of Practical Medicine, 2023, 39(6): 655-659.
[13]	CHEN Fukun, LV Juan, DENG Zhiyong. Effect of chimeric antigen receptor gene⁃modified T⁃cell immunotherapy for lung cancer：A systematic review [J]. The Journal of Practical Medicine, 2023, 39(5): 538-543.
[14]	WU Yang, LU Hanjie, SHUI Huifeng.. The efficacy and safety of anlotinib plus PD⁃1 blockades in patients with advanced non⁃small cell lung can⁃ cer previously treated with immunotherapy [J]. The Journal of Practical Medicine, 2023, 39(5): 572-578.
[15]	Huaming ZHANG,Wanshan HE,Yun HAN,Guanqiao CHEN,Bin CHEN,Zhifu WEI,Hengying WU,Bin. WEN. Screening of gene differential expression of adenosine deaminase RNA specific 1 in cervical cancer cells based on transcriptome sequencing technology [J]. The Journal of Practical Medicine, 2023, 39(24): 3169-3174.

Research progress of CD73/NT5E in glioblastoma

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 42

Related Articles 15

Recommended Articles

Metrics

Comments